Detalhe da pesquisa
1.
Investigating the immunological function of alpha-2-glycoprotein 1, zinc-binding in regulating tumor response in the breast cancer microenvironment.
Cancer Immunol Immunother;
73(3): 42, 2024 Feb 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38349455
2.
Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer.
Med Mol Morphol;
2024 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38619618
3.
Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
Breast Cancer Res;
25(1): 13, 2023 01 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36721218
4.
Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis.
Breast Cancer Res Treat;
197(2): 245-254, 2023 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36427119
5.
Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer.
Breast Cancer Res Treat;
197(3): 593-602, 2023 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36494460
6.
Identification of MicroRNAs Associated with Histological Grade in Early-Stage Invasive Breast Cancer.
Int J Mol Sci;
25(1)2023 Dec 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38203206
7.
Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis.
Breast Cancer Res Treat;
191(1): 1-14, 2022 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34613502
8.
Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer.
Mod Pathol;
35(12): 1812-1820, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35922548
9.
Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer.
Mod Pathol;
34(7): 1271-1281, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33526875
10.
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Breast Cancer Res;
22(1): 85, 2020 08 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32782013
11.
Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
Breast Cancer Res Treat;
181(3): 541-551, 2020 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32350677
12.
FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer.
Breast Cancer Res Treat;
181(2): 331-338, 2020 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32253685
13.
Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.
Breast Cancer Res Treat;
182(2): 267-282, 2020 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32445177
14.
The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.
Breast Cancer Res Treat;
179(1): 79-90, 2020 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31599393
15.
Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
Breast Cancer Res Treat;
179(2): 349-357, 2020 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31679074
16.
Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.
Breast Cancer Res Treat;
179(3): 557-564, 2020 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31707510
17.
Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer.
BMC Cancer;
20(1): 1068, 2020 Nov 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33158432
18.
Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype.
Pathobiology;
87(4): 218-231, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32645698
19.
Evaluation of overall and disease-free survival in patients with free flaps for oral cancer resection.
Microsurgery;
40(8): 859-867, 2020 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33085115
20.
Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.
Br J Cancer;
121(9): 776-785, 2019 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31558802